AR061484A1 - Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar - Google Patents

Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar

Info

Publication number
AR061484A1
AR061484A1 ARP070102645A ARP070102645A AR061484A1 AR 061484 A1 AR061484 A1 AR 061484A1 AR P070102645 A ARP070102645 A AR P070102645A AR P070102645 A ARP070102645 A AR P070102645A AR 061484 A1 AR061484 A1 AR 061484A1
Authority
AR
Argentina
Prior art keywords
antigen
genes
formulation
amino acid
acid sequences
Prior art date
Application number
ARP070102645A
Other languages
English (en)
Original Assignee
Dow Agrosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc
Publication of AR061484A1 publication Critical patent/AR061484A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

La presente solicitud provee secuencias de aminoácidos (que incluyen una secuencia de consenso) de una proteína hemaglutinina A del virus de gripe aviar. Estas construcciones genéticas recientes están disenadas para proveer un amplio espectro de actividades a través de la familia de serotipos proveyendo de esta manera, una base para una vacuna que tiene una amplia proteccion contra enfermedades heterologas. Los genes han sido además mejorados mediante la adicion de sitios de glicosilacion estratégicos en las secuencias de aminoácidos que ellas codifican. Estos genes pueden también, opcionalmente, ser un codon optimizado para la expresion de plantas, insertadas en el vector apropiado y donado en plantas para la expresion. Los polipéptidos producidos por células de huésped recombinantes o plantas transgénicas pueden también ser usados como fuente de antígeno para la formulacion de vacunas para el control de la gripe en individuos susceptibles. Adicionalmente, el material de plantas transgénicas puede también ser usado como fuente de antígeno para la formulacion de vacunas para el control de la gripe en individuos susceptibles. Reivindicacion 1: Un polipéptido aislado, purificado y/o recombinante que comprende las SEC ID N°: 2, 4, 6, 8, 10, 12 o 14.
ARP070102645A 2006-06-16 2007-06-15 Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar AR061484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81424106P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
AR061484A1 true AR061484A1 (es) 2008-08-27

Family

ID=38834237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102645A AR061484A1 (es) 2006-06-16 2007-06-15 Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar

Country Status (11)

Country Link
US (1) US8163876B2 (es)
EP (1) EP2029167A4 (es)
JP (1) JP2009540801A (es)
KR (1) KR20090027216A (es)
CN (1) CN101472607A (es)
AR (1) AR061484A1 (es)
AU (1) AU2007261196A1 (es)
BR (1) BRPI0713671A2 (es)
CA (1) CA2654178A1 (es)
WO (1) WO2007149715A2 (es)
ZA (1) ZA200808845B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410562B8 (pt) 2003-05-22 2021-05-25 Fralunhofer Usa Inc proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
CA2616859C (en) 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
AU2007261196A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2008140557A2 (en) 2006-10-24 2008-11-20 Samuel Bogoch A method of predicting influenza outbreaks
WO2008156914A2 (en) 2007-05-30 2008-12-24 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2720465A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
CN102165062B (zh) * 2008-07-18 2017-09-08 麦迪卡格公司 新的流感病毒免疫表位
US20120034253A1 (en) * 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
CA2759325A1 (en) * 2009-04-23 2010-10-28 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
CN101693894B (zh) * 2009-10-15 2011-07-27 北京大学深圳研究生院 禽流感病毒h5n1假病毒及其制备方法与专用dna片段
AR083533A1 (es) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
CN116218900A (zh) * 2011-09-30 2023-06-06 麦迪卡格公司 增加植物中病毒样颗粒的产率
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
WO2015048129A1 (en) * 2013-09-24 2015-04-02 CHOI, Duk, Kyung Avian influenza virus polypeptides and methods of their use
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
MX2023010985A (es) * 2021-03-18 2024-01-26 Calyxt Inc Matrices de celulas vegetales y procedimientos de las mismas.
CN118076389A (zh) * 2021-08-30 2024-05-24 日环科学株式会社 免疫赋活制剂及含有该免疫赋活制剂的化妆品、食品、饲料添加剂、准药品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100393870C (zh) * 2003-05-05 2008-06-11 波依斯汤普森植物研究所 用于制备免疫保护性组合物的载体和来源于转基因植物的细胞
EP1766059B1 (en) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
AR060565A1 (es) 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
AU2007261196A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin

Also Published As

Publication number Publication date
JP2009540801A (ja) 2009-11-26
US8163876B2 (en) 2012-04-24
CN101472607A (zh) 2009-07-01
AU2007261196A1 (en) 2007-12-27
EP2029167A4 (en) 2010-06-16
BRPI0713671A2 (pt) 2013-12-03
WO2007149715A3 (en) 2008-07-24
ZA200808845B (en) 2009-10-28
EP2029167A2 (en) 2009-03-04
CA2654178A1 (en) 2007-12-27
KR20090027216A (ko) 2009-03-16
US20090106864A1 (en) 2009-04-23
WO2007149715A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AR061484A1 (es) Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
ES2741729T3 (es) Vectores y construcciones de liberación de antígenos de virus de la gripe
AR125392A2 (es) Métodos y composiciones para la expresión génica en plantas
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
ATE552846T1 (de) Verbesserter grippeimpfstoff
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
IL288541B (en) Vaccine against rsv
JP2009540801A5 (es)
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
JP2009535306A5 (es)
CA3207612A1 (en) Composite antigenic sequences and vaccines
NZ627888A (en) Materials and methods for respiratory disease control in canines
NZ598605A (en) Vaccine against african horse sickness virus
SA520420568B1 (ar) جين متماثل من الديسموتاز فائق الأكسيد المستقر واستخداماته (sod)
Cargnelutti et al. Development of a universal CTL-based vaccine for influenza
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
MX381786B (es) Gen insecticida variante axmi115 y métodos para utilizarlo.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
Shi et al. Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine
CR20190249A (es) Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal